Founded in 2021, the medtech company Sedivention aims to facilitate the treatment of obesity with a novel cryo-catheter that cauterizes the gastric branches of the vagus nerve within minutes. The procedure can be performed on an outpatient basis, similar to a gastroscopy—as a one-time, minimally invasive procedure. This new, innovative, and cost-effective method is also expected to have positive effects on obesity-related complications such as diabetes and hypertension (high blood pressure).
Using fresh capital to further advance product development
An approach that the company has already used, among other things, in Munich Business Plan Competition And now the HTGF has also been convinced: the early-stage investor is pumping €800,000 into the young company. A prototype of the cryo-catheter has already been developed and successfully tested for safety and efficacy. Sedivention will use the raised capital to further advance product development.
Ute Nollert, founder of Sedivention, explains:
"Obesity is not a consequence of indiscipline, but a disease in its own right. We help people lose weight. Without surgery, without implants, without lifelong medication."
And Jan Engels, Investment Manager at HTGF, added:
“We are convinced by the idea and approach of Sedivention’s novel therapy and are pleased to be able to accompany the company in its next steps.”
